Takeda Moves To Add Indications For Velcade Blood-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical, new owner of U.S.-based Millennium Pharmaceuticals, plans to expand the approved indications for the subsidiary's Velcade (bortezomib) drug for multiple myeloma. Millennium's patent for the drug expires in the United States in 2017 and Takeda wants to extend its market life by seeking new uses for Velcade, such as for treating lymphomas. The drug is in Phase III trials for two types of lymphoma, non-Hodgkin for which it plans to apply by 2011, and mantle cell in 2012. On its own, Millennium is developing the drug as a subcutaneous injection, instead of its current venous form, and expects to seek approval for it in 2011. (Click here for more - a subscription may be required
|
Takeda Pharmaceutical, new owner of U.S.-based Millennium Pharmaceuticals, plans to expand the approved indications for the subsidiary's Velcade (bortezomib) drug for multiple myeloma. Millennium's patent for the drug expires in the United States in 2017 and Takeda wants to extend its market life by seeking new uses for Velcade , such as for treating lymphomas. The drug is in Phase III trials for two types of lymphoma, non-Hodgkin for which it plans to apply by 2011, and mantle cell in 2012. On its own, Millennium is developing the drug as a subcutaneous injection, instead of its current venous form, and expects to seek approval for it in 2011. (Click here for more - a subscription may be required) "Takeda Testing Cancer Drug Velcade Against Lymphomas In U.S." - Nikkei (5/28/09) |